FirstIgnite is supporting the commercialization of Binghamton University’s liposomal lidocaine formulation technology, which involves a newly developed topical lidocaine formulation that encapsulates the drug into flexible liposomes. This approach offers enhanced penetration and delivery to the targeted areas, reducing the need for painful injections.
This technology’s applications include the removal of facial tumors, skin tag/mole removal in sensitive areas, facial cosmetic procedures, dental surgery, and skin procedures in infants and children. The global skin cancer treatment market size was worth $8.19 billion in 2019 and is projected to reach $14.55 billion by 2027.
Binghamton University’s liposomal lidocaine formulation technology is ready for collaboration (licensing, partnerships, industry feedback, etc.). Is your company the right fit? If you’d be available for a conversation with the Binghamton University team, you can schedule a time directly on their team’s calendar here.
